ReviewNature reviews. Nephrology2015
Causes and pathogenesis of focal segmental glomerulosclerosis.
Review in Nature reviews. Nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
200 citing papers in PubMed, 1 synthesis or guideline pooled it, 342 citations in OpenAlex.
- Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review.Renal failure · 2023Pooled it
- Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.American journal of physiology. Renal physiology · 2018Trial
- Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.BMC nephrology · 2015Trial
- Epigallocatechin-3-gallate attenuates oxidative stress and apoptosis in podocytes of focal segmental glomerulosclerosis.Renal failure · 2026Article
- Single-cell transcriptomics and machine-learning reveal M1 macrophage-driven progression from minimal change disease to focal segmental glomerulosclerosis.Renal failure · 2026Article
- Inhibition of MAFB and PI3K/AKT Signaling for Hereditary FSGS with Multicentric Carpotarsal Osteolysis.Journal of the American Society of Nephrology : JASN · 2026Article
- Pigmented microcystic chromophobe renal cell carcinoma in a patient with end-stage kidney disease: Importance of evaluating non-neoplastic renal parenchyma.Urology case reports · 2026Article
- Baseline podocyte-associated state and persistent cell-matrix transcriptional programs are associated with BALB/c substrain differences in adriamycin nephropathy.Animal models and experimental medicine · 2026Article
- Serial Kidney Biopsies Reveal Progressive Pathology in Townes-Brocks Syndrome: A Case Report.Kidney medicine · 2026Article
- A case of hypertensive emergency in a patient who had a history of very low birth weight.CEN case reports · 2026Article
- Broadening the Phenotypic Spectrum ofGenes · 2026Article
- Gene modification: Exploring the potential in treating kidney diseases.Pharmacological research · 2026Review
- Mettl3-Mediated m6A Modification Represents a Novel Therapeutic Target for FSGS.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- From Usher syndrome to Bardet-Biedl syndrome: Diagnosis after an atypical presentation.Clinical nephrology. Case studies · 2026Article
- Cellular variant focal segmental glomerulosclerosis during trastuzumab emtansine treatment in HER2-positive breast cancer: a case report.Frontiers in oncology · 2026Article
- Short interference RNAs in glomerulonephritis: A mini review.BioImpacts : BI · 2026Review
- Multi-omics analyses demonstrate complement dysregulation is involved in focal segmental glomerulosclerosis.Frontiers in immunology · 2026Article
- Overlap of PR3-Positive ANCA-Associated Vasculitis and Primary Focal Segmental Glomerulosclerosis: A Case Report, Patient Perspective, and Review of the Literature.Canadian journal of kidney health and disease · 2026Article
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
- Pathogenic mechanisms in Fabry disease.Frontiers in medicine · 2026Review
140 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Focal segmental glomerulosclerosis (FSGS) describes both a common lesion in progressive kidney disease, and a disease characterized by marked proteinuria and podocyte injury. The initial injuries vary widely. Monogenetic forms of FSGS are largely due to alterations in structural genes of the podocyte, many of which result in early onset of disease. Genetic risk alleles in apolipoprotein L1 are especially prevalent in African Americans, and are linked not only to adult-onset FSGS but also to progression of some other kidney diseases. The recurrence of FSGS in some transplant recipients whose end-stage renal disease was caused by FSGS points to circulating factors in disease pathogenesis, which remain incompletely understood. In addition, infection, drug use, and secondary maladaptive responses after loss of nephrons from any cause may also cause FSGS. Varying phenotypes of the sclerosis are also manifest, with varying prognosis. The so-called tip lesion has the best prognosis, whereas the collapsing type of FSGS has the worst prognosis. New insights into glomerular cell injury response and repair may pave the way for possible therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.